PR3-ANCA: A promising biomarker for ulcerative colitis with extensive disease

Clinica Chimica Acta

Volumn 424, Issue , 2013, Pages 267-273

  Mahler, Michael ^a   Bogdanos, Dimitrios P ^b   Pavlidis, Polychronis ^b,c   Fritzler, Marvin J ^d   Csernok, Elena ^e   Damoiseaux, Jan ^f   Bentow, Chelsea ^a   Shums, Zakera ^a   Forbes, Alastair ^c   Norman, Gary L ^a  

^a INOVA DIAGNOSTICS INC   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF LÜBECK   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune disease; Crohn's disease; Inflammatory bowel disease; PR3 ANCA; Ulcerative colitis

Indexed keywords

MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS;

ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY; ASCA; AUTOIMMUNE DISEASE; CALCULATED UNITS; CANCA; CHEMILUMINESCENCE ASSAY; CIA; CRD; CROHN'S DISEASE; CU; CYTOPLASMIC ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; GPA; GRANULOMATOSIS WITH POLYANGIITIS; IBD; IIF; INDIRECT IMMUNOFLUORESCENCE ASSAY; INFLAMMATORY BOWEL DISEASE; LIA; LINE IMMUNOASSAY; PANCA; PERINUCLEAR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES; PR3-ANCA; UC; ULCERATIVE COLITIS; WEGENER'S GRANULOMATOSIS; WG;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84880409853     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.06.005     Document Type: Article

References (51)

1. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
2. Joossens S., Reinisch W., Vermeire S., et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002, 122:1242-1247.
3. Papp M., Norman G.L., Altorjay I., Lakatos P.L. Utility of serological markers in inflammatory bowel diseases: gadget or magic?. World J Gastroenterol 2007, 13:2028-2036.
4. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 140:1817-1826.
5. Papp M., Altorjay I., Lakos G., et al. Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Clin Vaccine Immunol 2009, 16:464-470.
6. Lochman I., Kral V., Lochmanova A., Lupac J., Cebecauer L. ANCA in the diagnosis of neutrophil-mediated inflammation. Autoimmun Rev 2011, 10:295-298.
7. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181.
8. Reese G.E., Constantinides V.A., Simillis C., et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006, 101:2410-2422.
9. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
10. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
11. Wiik A. What you should know about PR3-ANCA. An introduction. Arthritis Res. 2000, 2:252-254.
12. Terjung B., Spengler U., Sauerbruch T., Worman H.J. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000, 119:310-322.
13. Csernok E., Holle J., Hellmich B., et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2004, 43:174-180.
14. Arranz O., Ara J., Rodriguez R., et al. Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients. Clin Nephrol 2001, 56:295-301.
15. Sun J., Fass D.N., Hudson J.A., et al. Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. J Immunol Methods 1998, 211:111-123.
16. Roggenbuck D., Buettner T., Hoffmann L., Schmechta H., Reinhold D., Conrad K. High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. Ann N Y Acad Sci 2009, 1173:41-46.
17. Holle J.U., Csernok E., Fredenhagen G., Backes M., Bremer J.P., Gross W.L. Clinical evaluation of hsPR3-ANCA ELISA for detection of antineutrophil cytoplasmatic antibodies directed against proteinase 3. Ann Rheum Dis 2010, 69:468-469.
18. Rutgers A., Damoiseaux J., Roozendaal C., Limburg P.C., Stegeman C.A., Tervaert J.W. ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis. J Clin Immunol 2004, 24:435-440.
19. Kaul R., Johnson K., Scholz H., Marr G. Performance of the BioPlex 2200 Autoimmune Vasculitis kit. Autoimmun Rev 2009, 8:224-227.
20. Trevisin M., Pollock W., Dimech W., Savige J. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD). J Immunol Methods 2008, 336:104-112.
21. Damoiseaux J., Dahnrich C., Rosemann A., et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009, 68:228-233.
22. Ito-Ihara T., Muso E., Kobayashi S., et al. A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe. Clin Exp Rheumatol 2008, 26:1027-1033.
23. Hellmich B., Csernok E., Fredenhagen G., Gross W.L. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 2007, 25:S1-S5.
24. Ooi C.J., Lim B.L., Cheong W.K., Ling A.E., Ng H.S. Antineutrophil cytoplasmic antibodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study. Ann Acad Med Singapore 2000, 29:704-707.
25. Bogdanos D.P., Rigopoulou E.I., Smyk D.S., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148.
26. Op De Beeck K., Vermeire S., Rutgeerts P., Bossuyt X. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2012, 61:162-164.
27. Joossens S., Daperno M., Shums Z., et al. Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis. Clin Chem 2004, 50:1422-1425.
28. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6.
29. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
30. Mahler M., Radice A., Yang W., et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012, 413:719-726.
31. Savige J., Dimech W., Fritzler M., et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003, 120:312-318.
32. Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol (in press).
33. Terjung B., Sohne J., Lechtenberg B., et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 59:808-816.
34. Lee A.S., Finkielman J.D., Peikert T., Hummel A.M., Viss M.A., Specks U. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Methods 2005, 307:62-72.
35. O'Donnell J.L., Hayman M.W., Spellerberg M.B., et al. Antineutrophil cytoplasmic antibody measurement: advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA. Pathology 2007, 39:258-263.
36. Russell K.A., Wiegert E., Schroeder D.R., Homburger H.A., Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002, 103:196-203.
37. Elzouki A.N., Eriksson S., Lofberg R., Nassberger L., Wieslander J., Lindgren S. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 1999, 5:246-252.
38. Xu J., Yang C.H., Chen X.Y., Li X.H., Dai M., Xiao S.D. A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol 2008, 14:7012-7015.
39. Specks U. What you should know about PR3-ANCA. Conformational requirements of proteinase 3 (PR3) for enzymatic activity and recognition by PR3-ANCA. Arthritis Res 2000, 2:263-267.
40. Peen E., Williams R.C. What you should know about PR3-ANCA. Structural aspects of antibodies to proteinase 3 (PR3). Arthritis Res 2000, 2:255-259.
41. Jenne D.E., Kuhl A. Production and applications of recombinant proteinase 3, Wegener's autoantigen: problems and perspectives. Clin Nephrol 2006, 66:153-159.
42. van der Geld Y.M., Stegeman C.A., Kallenberg C.G. B cell epitope specificity in ANCA-associated vasculitis: does it matter?. Clin Exp Immunol 2004, 137:451-459.
43. van der Geld Y.M., Oost-Kort W., Limburg P.C., Specks U., Kallenberg C.G. Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods 2000, 244:117-131.
44. Wiik A. Autoantibodies in vasculitis. Arthritis Res Ther 2003, 5:147-152.
45. Schwarze C., Terjung B., Lilienweiss P., et al. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol 2003, 133:283-289.
46. Civan J.M., Gilbert C.R., Kastenberg D.M. Pulmonary capillaritis: a rare extra-intestinal manifestation of inflammatory bowel disease. Am J Gastroenterol 2011, 106:804-805.
47. Beccastrini E., Emmi G., Squatrito D., Nesi G., Almerigogna F., Emmi L. Lobular panniculitis with small vessel vasculitis associated with ulcerative colitis. Mod Rheumatol 2011, 21:531.
48. Qian Q., Cornell L., Chandan V., Hartman R., Caples S. Hemorrhagic colitis as a presenting feature of Wegener granulomatosis. J Gastrointestin Liver Dis 2010, 19:445-447.
49. Pagnoux C., Mahr A., Cohen P., Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Med (Baltimore) 2005, 84:115-128.
50. Burke A., Sobin L., Virmani R. Localized vasculitis of the gastrointestinal tract. Am J Surg Pathol 1995, 19:338-349.
51. Roozendaal C., Kallenberg C.G. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?. Clin Exp Immunol 1999, 116:206-213.